Dr. David Rhew jumps from Samsung to Microsoft, Happify Health names new CMO and other digital health hires

Also: Sword Health appoints new clinical advisory board; AbleTo brings in new medical director.
By Laura Lovett
Share

Dr. David Rhew has announced that he is leaving Samsung, where he served as the chief medical officer and VP of Enterprise Healthcare, to join Microsoft as the new chief medical officer and VP of healthcare at the Worldwide Commercial Business division. According to a Microsoft blog post announcing his new position, Rhew holds six U.S. patents for clinical decision support systems, interoperability and integration of EHR data. 

“Data are quickly becoming the new currency in healthcare. Organizations that create value through secure storage, clinical interpretation, and the seamless exchange of data between patients and providers are emerging as the new leaders. Microsoft is positioned to lead in this capacity. I am honored to be a part of the team that builds and grows this business,” Rhew said in a statement. 


Happify Health, a platform that looks to help users maintain their well-being and prevent diagnosable mental health conditions, has named Dr. Murry Zucker as the new medical director. Zucker was formerly the chief medical officer for CHESS Health and senior medical director of new product and innovation at Optum. He is a trained psychiatrist and will be overseeing clinical trials and research, as well as coordinating with mental health professionals. 

"Dr. Zucker's background as a psychiatrist — combined with his expertise in behavior change, patient engagement and new technologies — makes him particularly well-suited to assume this leadership role and expand our footprint in the digital therapeutics space," Tomer Ben-Kiki, co-founder and CEO of Happify Health, said in a statement.


Digital physical therapy company Sword Health has announced a new clinical advisory board with Dr. Jose Rodriguez as its chairman. Rodriguez is an orthopedic surgeon at the Hospital for Special Surgery and serves on the board of the Journal of Arthroplasty. Dr. Jorge Lains, president of the International Society of Physical and Rehabilitation Medicine; Dr. Gerard Francisco, the chairman of McGovern Medical School; and Dr. Chris Furmansky, director of innovation at Stanford Health Care, will also be joining the board. 


Digital behavioral health company AbleTo announced that Dr. David Whitehouse will be joining the team as medical director. Prior to this role, Whitehouse served as a consultant for MCG Health. 

“AbleTo is setting the bar for high-quality care delivery in the market, and I’m honored to join an organization with such an impressive dedication to clinical quality and outcomes measurement,” Whitehouse said in a statement. “I look forward to contributing to the impressive track record of innovation, and helping to shape the future of technology-enabled behavioral health care.”


Earlier this week AccessOne, a fintech company designed to help patients manage their healthcare costs, announced that Craig Rosato will be joining as CFO. The company also tapped Tammy Geis as the next COO. 

Rosato has previously worked for Bank of America and Ernst & Young. Geiser is stepping into the new COO role from the CFO position. 

“AccessOne continues to attract and retain strong talent.  Our team is the key to our success,” Mark Spinner, CEO of AccessOne, said in a statement. “Craig and Tammy each bring a unique set of skills and invaluable years of experience to the company, and we’re eager to expand our leadership in solving the consumer’s need for convenient, affordable financing options at the point of care.”


Connected health company Biolog-id has named Troy Hilsenroth as the company’s next CEO. Hilsenroth is coming from his role as VP and general manager of the medication adherence division at Omnicell.

“We are at a critical point in our evolution and need to strengthen our executive team with the best leadership and expertise,” Pierre Parent, president of Biolog-id, said in a statement. “Troy has in-depth healthcare experience with a proven track record of execution. His strong leadership and customer-first approach will help Biolog-id capitalize on the market opportunity in North America and reinforce our commitment to establishing innovative solutions for patients and our customers.”